A new JAMA Oncology study found that Individuals with obesity taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) demonstrated 17% lower cancer risk compared to non-users. AACE President Scott D. Isaacs, MD, FACP, FACE, explained that the findings suggest GLP-1 medications may be associated with decreased cancer risk in people with obesity, while noting that observational data show association rather than causation and that longer-term studies in high-risk MASLD patients are needed. He added that GLP-1RA medications may represent a comprehensive therapeutic approach in metabolic medicine, treating multiple diseases simultaneously. Learn more by reading the full article on MedCentral.